| Date Filed | Type | Description |
| 08/16/2023 |
4
| Struthers Richard Scott (President & CEO) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Exercised 10,000 options to buy
@ $1.91, valued at
$19.1k
|
|
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
4
| Struthers Richard Scott (President & CEO) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Sold 24,384 shares
@ $20.14, valued at
$491.1k
Sold 11,459 shares
@ $20.17, valued at
$231.1k
Sold 14,157 shares
@ $20.35, valued at
$288.1k
|
|
| 07/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
4
| Vivaldi Coelho Rogerio (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Bought 5,000 shares
@ $22.06, valued at
$110.3k
|
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/05/2023 |
4
| Pizzuti Dana (Chief Development Officer) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 4,288 shares
@ $15.98, valued at
$68.5k
Sold 8,212 shares
@ $16.15, valued at
$132.6k
|
|
| 03/17/2023 |
4
| Wilson Marc (CFO) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 1,666 shares
@ $17.12, valued at
$28.5k
|
|
| 03/17/2023 |
4
| Struthers Richard Scott (President & CEO) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 4,628 shares
@ $17.12, valued at
$79.2k
|
|
| 03/17/2023 |
4
| Krasner Alan Seth (Chief Medical Officer) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 1,687 shares
@ $17.12, valued at
$28.9k
|
|
| 03/17/2023 |
4
| Knight Jeff E. (COO) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 587 shares
@ $17.12, valued at
$10k
|
|
| 03/17/2023 |
4
| Betz Stephen F. (Chief Scientific Officer) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 1,410 shares
@ $17.12, valued at
$24.1k
|
|
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 02/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 5.9% stake in Crinetics Pharmaceuticals Inc. |
| 02/14/2023 |
SC 13G
| BRAIDWELL LP reports a 6.4% stake in CRINETICS PHARMACEUTICALS INC |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.1% stake in Crinetics Pharmaceuticals, Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| DRIEHAUS CAPITAL MANAGEMENT LLC reports a 10.4% stake in Crinetics Pharmaceuticals, Inc. |
| 02/06/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2023 |
SC 13G/A
| BlackRock Inc. reports a 7.3% stake in Crinetics Pharmaceuticals, Inc. |
| 01/27/2023 |
5
| Wilson Marc (CFO) has filed a Form 5 on Crinetics Pharmaceuticals, Inc. |
| 01/27/2023 |
5
| Krasner Alan Seth (Chief Medical Officer) has filed a Form 5 on Crinetics Pharmaceuticals, Inc. |
|